Mutations in the parkin gene are a common cause of autosomal recessive early-onset parkinsonism. Parkin functions as an E3 ubiquitin ligase where it can polyubiquitinate a number of its protein substrates, thus targeting them for degradation by the 26 S proteasomal complex. Recent studies have demonstrated that alternative modes of parkin-mediated ubiquitination may serve other non-degradative regulatory roles. In addition, parkin appears to function as a multipurpose neuroprotectant in a number of toxic paradigms. Coupled with these observations, parkin may integrate other gene products associated with parkinsonism, including α-synuclein, LRRK2 (leucine-rich repeat kinase 2), DJ-1 and PINK1 [PTEN (phosphatase and tensin homologue deleted on chromosome 10)-induced putative kinase 1], into a common biochemical pathway of potential relevance to disease pathogenesis. Parkin therefore represents a unique multifaceted ubiquitin ligase consistent with an important housekeeping role in maintaining the integrity or survival of dopaminergic neurons.
Introduction
PD (Parkinson's disease) is a progressive neurodegenerative movement disorder characterized primarily by the death of nigrostriatal dopaminergic neurons and the appearance of intracytoplasmic proteinaceous inclusions termed Lewy bodies. Although PD is primarily a sporadic disorder of unclear aetiology, the identification of genes associated with rare monogenic forms of the disease has provided tremendous insight into the molecular mechanisms involved in disease pathogenesis. To date, genetic mutations in α-synuclein, parkin, DJ-1, PINK1 [PTEN (phosphatase and tensin homologue deleted on chromosome 10)-induced putative kinase 1] and LRRK2 (leucine-rich repeat kinase 2) have been identified to unambiguously cause familial parkinsonism [1] . A plethora of mutations in the parkin gene (PARK2; OMIM 600116), including missense mutations and rearrangements, commonly cause a distinct early-onset form of PD referred to as AR-JP (autosomal recessive juvenile parkinsonism) characterized, for the most part, by pure nigral degeneration and the absence of Lewy bodies [2, 3] .
Parkin is an E3 ubiquitin ligase
The parkin gene encodes a 465-amino-acid protein with a modular structure containing an N-terminal ubiquitin-like domain and a C-terminal RING (really interesting new gene) domain composed of two RING finger motifs separated by an in-between RING finger domain. Similar to other RING finger proteins, parkin functions as an E3 ubiquitin protein ligase [4] [5] [6] . Ubiquitin ligases are an essential component of the cellular machinery that covalently modifies protein substrates with ubiquitin, a 76-amino-acid polypeptide. Ubiquitination results from the highly co-ordinated and successive actions of ubiquitin-activating (E1), -conjugating (E2) and -ligase (E3) enzymes respectively where the E3 ligase primarily confers substrate specificity by catalysing the conjugation of ubiquitin to a lysine residue of the substrate [7] . Subsequent cycles of ubiquitination through conjugation of the C-terminal glycine residue of a new ubiquitin monomer to an internal lysine residue of the previously ligated ubiquitin, leads to the formation of a polyubiquitin chain that is best known for targeting recipient proteins to the 26 S proteasome for degradation. Independent of proteasomal degradation, ubiquitination of proteins commonly regulates a number of important cellular processes including postreplicative DNA repair, transcriptional and translational regulation, endocytosis, protein trafficking and lysosomal degradation [7, 8] .
Parkin, the ubiquitin-proteasome system and parkinsonism Consistent with its function as an E3 ubiquitin ligase, parkin interacts with and can utilize a number of E2s including UbcH7, UbcH8, Ubc6, Ubc7 and UbcH13/Uev1 to assemble polyubiquitin chains [4] [5] [6] 9, 10] . The vast majority of diseaseassociated mutations in parkin are considered to produce a loss of function and tend to differentially disrupt ubiquitin ligase activity, expression, intrinsic solubility, cellular localization or interaction with E2s and substrates [11] [12] [13] [14] . The observation that AR-JP probably results from a loss of parkin function suggests that parkin-mediated ubiquitination of specific cellular substrates is required for the survival of nigrostriatal dopaminergic neurons. In the absence of parkin what therefore is responsible for the death of dopaminergic neurons? It is widely suggested that parkin mutations result in the improper targeting of specific protein substrates to the proteasome for degradation, which leads to their potentially neurotoxic accumulation. While there is evidence in support of this notion for some parkin substrates, there also remains a paucity of data for other substrates, which convincingly demonstrates that parkin mediates their polyubiquitination and/or proteasomal degradation (refer to Table 1 ). So far, a number of putative substrates for parkin have been identified [4, 9, [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] . Non-ubiquitinated forms of O-glycosylated α-synuclein, Pael-R (parkin-associated endothelin-like receptor), cyclin E, CDCrel-1 (cell division control-related protein 1), CDCrel-2a, p38/JTV-1 and FBP1 (far upstream sequence element-binding protein 1) have been shown to accumulate in brain tissue from parkin-linked AR-JP cases, suggesting that parkin may normally contribute to their turnover in vivo. Both p38/JTV-1 and FBP1 have also been shown to accumulate in brain tissue from parkin-deficient mice and sporadic PD cases, leading to the suggestion that they may represent authentic parkin substrates [16, 18] . An authentic parkin substrate might be defined by (i) its parkinmediated polyubiquitination, (ii) its accelerated, proteasomal-dependent turnover in the presence of parkin, (iii) its neurotoxicity when overexpressed, especially towards dopaminergic neurons, and (iv) its accumulation as a non-ubiquitinated species in brain tissue from parkin-deficient mice and AR-JP cases. So far, only p38/JTV-1 [18] (and perhaps CDCrel-1 [4, 23, 27, 28] ) adheres to these criteria, raising doubts about the authenticity of other putative parkin substrates.
Contrary to expectation, proteomic analysis of ventral midbrain tissue from one line of parkin-deficient mice has actually revealed reduced levels of several proteins involved in mitochondrial oxidative phosphorylation and protection from oxidative stress together with a reduction in mitochondrial respiratory capacity and progressive oxidative damage [29] . These findings support an unexpected role for parkin in the normal regulation and/or maintenance of mitochondrial function, which is supported by observations in parkindeficient Drosophila models. Such fly models exhibit reduced lifespan, locomotor defects, apoptotic muscle degeneration and male sterility of which the earliest manifestation appears to be mitochondrial pathology and increased oxidative stress [30, 31] . Thus mitochondrial defects and increased oxidative stress in parkin-deficient mice and flies may represent the primary pathogenic events relevant to parkin-linked AR-JP that would eventually trigger nigrostriatal dopaminergic neuronal degeneration. It is at present unclear how the absence of parkin in neurons precipitates deficits in mitochondrial function and whether or not this relates to the simple toxic accumulation of a particular parkin substrate or instead perhaps relates to an inherent non-degradative regulatory role for parkin-mediated ubiquitination.
Parkin-mediated ubiquitination: more than just degradation?
While a critical role for parkin-mediated polyubiquitination in degrading substrates through the ubiquitin-proteasome system is perhaps the simplest explanation for how dopaminergic neurons degenerate in the absence of parkin, accumulating evidence demonstrates that parkin can additionally mediate modes of ubiquitination that are non-degradative, suggestive of an alternative regulatory role for parkin. For example, parkin can ubiquitinate the α-synuclein-interacting protein, synphilin-1, with both Lys 48 -or Lys 63 -linked polyubiquitin chains [17] . Parkin normally mediates the Lys 63 -linked ubiquitination of synphilin-1, which does not lead to its degradation via the proteasome. Furthermore, parkinmediated ubiquitination of proteins within Lewy body-like inclusions formed by the co-expression of synphilin-1, α-synuclein and parkin occurs predominantly via Lys 63 ubiquitin linkages, and the formation of such inclusions is even enhanced by Lys 63 -linked ubiquitination [17] . However, only at an unusually high parkin/synphilin-1 expression ratio does parkin favour Lys 48 -linked ubiquitination of synphilin-1 leading to its degradation by the proteasome. This observation suggests that parkin uniquely represents a dual-function ubiquitin ligase. Recombinant parkin has recently been shown to support both Lys 48 -and Lys 63 -linked polyubiquitin chain assembly in vitro in rabbit reticulocyte fractions [10] , further supporting its proposed dual functionality. Lys 63 -linked polyubiquitin chains have been associated with nondegradative processes including DNA repair, IκBα (inhibitory κBα) kinase activation, endocytosis and translational regulation [8] .
An interesting feature of parkin is its ability to mediate auto-ubiquitination, which can give rise to high-molecularmass Lys 48 -linked polyubiquitinated parkin species in cultured cells that accumulate following proteasome inhibition [6] . However, in vitro ubiquitination experiments with recombinant components demonstrate that parkin can intrinsically mediate its own multiple mono-ubiquitination, utilizing the E2s UbcH13/Uev1, Ubc7 or UbcH7 [11, 12] . In addition to itself, parkin can also mediate the multiple mono-ubiquitination of p38/JTV-1 in cultured cells, which may contradict the accumulation of this protein in brain tissue from parkin-deficient AR-JP cases and mice [12] . Our laboratory has recently identified the molecular chaperone, Hsp70 (heat-shock protein 70), as a novel substrate for the ubiquitin ligase activity of parkin where it undergoes multiple mono-ubiquitination both in vitro and in cultured cells [32] . Consistent with a non-degradative role for this mode of ubiquitination, parkin fails to promote the proteasomal degradation or turnover of Hsp70 and, moreover, the levels of Hsp70 are not altered in brain tissue from parkin-linked AR-JP cases [32] . These observations support a non-degradative, regulatory role for parkin-mediated multiple mono-ubiquitination. Therefore, to date, parkin has been shown to mediate both Lys 48 -and Lys 63 -linked polyubiquitin chain assembly, as well as multiple mono-ubiquitination, demonstrating that parkin is a unique multifunctional E3 ligase. Our current understanding of the ubiquitin ligase activity of parkin therefore lends support both to the 'toxic substrate accumulation' hypothesis and to the loss of a critical nondegradative regulatory function for ubiquitination as the primary cause of parkin-linked AR-JP.
Parkin is a multipurpose neuroprotectant
While parkin appears to be a multifunction E3 ubiquitin ligase, it can also be viewed as a multipurpose neuroprotectant in that functional parkin can afford protection against a diverse array of toxic or stressful agents [33] . In a variety of model systems, parkin has been shown to mediate neuroprotection against mitochondrial-dependent apoptosis [34] , dopamine-mediated toxicity [35] , kainate-induced excitotoxicity [20] , the toxicity associated with overexpression of parkin substrates or other proteins (Pael-R [9, 36] , p38/JTV-1 [18, 22] , mutant α-synuclein [36] [37] [38] , CDCrel-1 [39] , mutant tau [40, 41] and an expanded polyglutamine ataxin-3 fragment [19] ), proteasomal inhibition [38] , mitochondrial toxins (MPP + and rotenone) [42, 43] and manganese toxicity [44] , among others. In the intriguing case of α-synuclein, parkin can seemingly protect against the selective loss of dopaminergic neurons induced by neuronal overexpression of mutant α-synuclein in Drosophila [36] . The mechanism for this protection is unclear since parkin does not appear to directly interact with or modify native α-synuclein [25] . It is possible that alterations in the structural conformation of α-synuclein perhaps through post-translational modifications (phosphorylation, nitration or O-glycosylation), oligomerization or fibrillization might permit an interaction with parkin, possibly through convergence on a common molecular pathway or protein. Consistent with this idea, parkin can suppress the neurotoxic effects of mutant α-synuclein by obscurely rescuing impaired proteasomal function [38] or through activation of the cysteine protease, calpain [45] . However, in mutant α-synuclein transgenic mice, inactivation of parkin has no apparent effect on α-synuclein-induced neurodegeneration [46] , thus questioning the protective capacity of parkin towards mutant α-synuclein in animal models. In general, the broad neuroprotective capacity of parkin might relate to its ability to mediate alternative modes of ubiquitination, and suggests a general housekeeping or maintenance role for parkin-mediated ubiquitination in neurons, consistent with the large number of putative parkin substrates.
Parkin: a common pathway to parkinsonism?
Consistent with its multifaceted function, recent studies suggest that parkin may provide a common link between gene products unambiguously associated with familial parkinsonism. The relationship between parkin and α-synuclein is outlined above. Parkin can interact with LRRK2 and promote the formation and ubiquitination of LRRK2-positive cytoplasmic aggregates in cultured cells, and in a reciprocal fashion, LRRK2 can specifically enhance the auto-ubiquitination activity of parkin [47] . Parkin also shares a novel relationship with DJ-1 where they can interact during oxidative stress or when DJ-1 harbours disease-associated mutations, but not under normal circumstances in cultured cells [48] . A novel genetic interaction between parkin and PINK1 has also recently been demonstrated in Drosophila [49, 50] . Inactivation of PINK1 in Drosophila results in a defective mitochondrial phenotype with marked similarities to that observed in parkin-deficient flies. Transgenic expression of parkin in PINK1-null flies rescues their phenotype, but not vice versa, suggesting that parkin functions downstream of PINK1 in the same molecular pathway. In keeping with this observation, PINK1 can specifically interact with parkin in cultured cells, which renders parkin largely inactive and insoluble (see Figure 1 phosphorylation (see Figure 1) . Therefore parkin shares novel relationships with α-synuclein, LRRK2, DJ-1 and PINK1 to varying levels. The significance of these observations is unclear at present but may suggest that the multifaceted function of parkin could provide a common link or biochemical pathway through which all PD-associated gene products converge to regulate the survival or otherwise of dopaminergic neurons and the development of parkinsonism.
Conclusions
The capacity of parkin to catalyse multiple modes of ubiquitin attachment to its many putative substrates, its role as a multipurpose neuroprotectant and its ability to influence other gene products associated with PD indicate that parkin is a unique multifaceted ubiquitin ligase with an important regulatory role in the maintenance of mitochondrial integrity. Parkin may play an important role in a common biochemical pathway central to the pathogenesis of familial and sporadic parkinsonism. Future studies will help to clarify the precise physiological function of parkin within neurons, especially dopaminergic neurons, and will contribute significantly to our understanding of the molecular pathogenesis of sporadic PD. 
